Veru Inc. (NASDAQ: VERU) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The company posted a narrower loss for Q2 as the substantial growth in prescription sales of FC2 drove the top-line higher.
On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks.
The company believes that VERU-111, a microtubule depolymerization agent that has broad antiviral activity, could be effective against the SARS CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to cause infection.
Past Performance
Most Popular
Infographic: How Cintas (CTAS) performed in Q1 2021
Cintas Corporation (NASDAQ: CTAS) reported first quarter 2021 earnings results today. Revenue was $1.75 billion, down 3.6% year-over-year. Net income rose 19% to $300 million, or $2.78 per share, from
General Mills Q1 results top Wall Street expectations: Infographic
General Mills (NYSE: GIS) reported first-quarter 2020 financial results before the opening bell on Wednesday. The company reported a 9% increase in Q1 revenues to $4.36 billion, beating the Wall
JinkoSolar (JKS) Q2 Earnings: Key financials and quarterly highlights
JinkoSolar Holding Co., Ltd. (NYSE: JKS) reported second quarter 2020 earnings results today. Total revenues increased 22.2% year-over-year to RMB8.45 billion ($1.20 billion), exceeding the company’s guidance of $1.10 billion to $1.18 billion. The growth was